GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Prenetics Global Ltd (NAS:PRE) » Definitions » ROCE %

PRE (Prenetics Global) ROCE % : -25.24% (As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Prenetics Global ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Prenetics Global's annualized ROCE % for the quarter that ended in Sep. 2024 was -25.24%.


Prenetics Global ROCE % Historical Data

The historical data trend for Prenetics Global's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prenetics Global ROCE % Chart

Prenetics Global Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROCE %
- -12.08 -356.16 -130.88 -24.08

Prenetics Global Quarterly Data
Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -20.58 -29.25 -17.66 -22.49 -25.24

Prenetics Global ROCE % Calculation

Prenetics Global's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-56.549/( ( (312.131 - 57.195) + (254.171 - 39.484) )/ 2 )
=-56.549/( (254.936+214.687)/ 2 )
=-56.549/234.8115
=-24.08 %

Prenetics Global's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Sep. 2024 )  (Q: Jun. 2024 )(Q: Sep. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Sep. 2024 )  (Q: Jun. 2024 )(Q: Sep. 2024 )
=-48.132/( ( (233.307 - 38.288) + (235.766 - 49.318) )/ 2 )
=-48.132/( ( 195.019 + 186.448 )/ 2 )
=-48.132/190.7335
=-25.24 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Prenetics Global  (NAS:PRE) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


Prenetics Global ROCE % Related Terms

Thank you for viewing the detailed overview of Prenetics Global's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Prenetics Global Business Description

Traded in Other Exchanges
N/A
Address
Unit 703-706, K11 Atelier King’s Road, 728 King’s Road, Quarry Bay, Hong Kong, HKG
Prenetics Global Ltd is a health sciences company dedicated to consumer and clinical health. Its consumer initiative is led by IM8, a new health and wellness brand, and Europa, a U.S. sports distribution company. The clinical division is led by Insighta, focused on multi-cancer early detection technologies. This is followed by ACT Genomics, which has achieved FDA clearance for genomic profiling of solid tumors, and CircleDNA, which uses NGS to offer DNA tests. Each Prenetics unit impacts health by 'enhancing life through science'.